Dec 12, 2017· Comment from Association for Accessible Medicines· FDA-2017-D-5868-0003
Comments from The Association for Accessible Medicines (AAM), on behalf of our member companies, regarding Docket FDA-2017-D-5868: Requests for Reconsideration at the Division Level Under GDUFA.